Invention Application
- Patent Title: METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES
-
Application No.: US15668824Application Date: 2017-08-04
-
Publication No.: US20170369549A1Publication Date: 2017-12-28
- Inventor: Robert James PEACH , Joseph Naemura , Peter S. Linsley , Jurgen Bajorath
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Main IPC: C07K14/725
- IPC: C07K14/725 ; A61K38/17 ; C07K14/705 ; C12N5/0783 ; C07H21/04 ; A61K39/395 ; A61K38/00 ; A61K39/00
Abstract:
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Public/Granted literature
- US10370428B2 Methods of treatment using CTLA4 mutant molecules Public/Granted day:2019-08-06
Information query
